I won't truly be 2yrs out from treatment until September 2026. Should I get a CT scan in July 2026

May 18, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Should You Get a CT Scan in July 2026? (Pre-2-Year Mark)

This is a smart, specific question — and the answer depends on a few factors I want to walk through with you.

The Timing Context

You're asking about getting a CT scan 2 months before your 2-year treatment completion anniversary. Let me explain why this timing matters for your clear cell/endometrial cancer.


What the Evidence Shows for Your Situation

According to NCCN Guidelines for Ovarian Cancer, the surveillance approach for early-stage patients (you're Stage 1C2) focuses on:

  • Clinical evaluation as the primary tool
  • CA-125 monitoring at regular intervals
  • Imaging clinically indicated — meaning ordered when there's a clinical reason, not on a fixed schedule

Key point: The guidelines don't recommend routine "anniversary" CT scans just because a certain time has passed. Instead, imaging is ordered based on:

  • Symptoms or clinical findings
  • Rising CA-125
  • Physical exam concerns
  • Specialist judgment about individual risk

Why July 2026 Might Actually Be Strategic for YOU

However, there are specific reasons a pre-2-year scan could make sense in your case:

Reason 1: Clear Cell's Recurrence Pattern

  • Clear cell has higher early recurrence risk (0-2 years)
  • Most recurrences happen in this window
  • A scan at the 2-year mark serves as a "reassurance baseline" — showing you're clear at the highest-risk point
  • Doing it in July (2 months early) vs. September doesn't change much clinically

Reason 2: Your CA-125 Reliability

  • Your CA-125 has been normal for 2 years — excellent
  • BUT clear cell cancers can recur with normal CA-125
  • A CT at the 2-year mark could provide reassurance that your normal CA-125 is actually reliable for you going forward
  • This helps you know: "If my CA-125 stays normal AND my CT was clear, I can trust that marker"

Reason 3: Psychological/Peace of Mind

  • After Abraxane chemotherapy and hysterectomy, reaching the 2-year mark is psychologically significant
  • A clear CT can provide genuine reassurance as you transition to longer surveillance intervals
  • This is legitimate — anxiety management matters for quality of life

Questions to Ask Your Oncologist About July 2026

Rather than me deciding for you, here's what to discuss:

  1. "Would you recommend a CT scan around my 2-year mark (July vs. September 2026)? Why or why not?"

  2. "Given my clear cell histology and normal CA-125, what would a clear CT tell us about my future surveillance?"

  3. "If I get a CT in July and it's clear, how does that change my surveillance strategy going forward?"

  4. "What's your typical approach — do you do 'reassurance scans' at the 2-year mark for clear cell patients?"

  5. "If I don't get a CT now, when would you recommend one — year 3? Year 5?"

  6. "Are there any symptoms or findings between now and July 2026 that would change this plan?"


The Practical Considerations

Arguments FOR a July 2026 CT:

  • ✅ You're at the end of the highest-risk window (0-2 years)
  • ✅ Provides baseline for future comparison
  • ✅ Reassurance that normal CA-125 is reliable for you
  • ✅ Helps transition to longer surveillance intervals (year 3-5)
  • ✅ Clear cell behavior warrants extra vigilance at this milestone

Arguments AGAINST routine CT:

  • ❌ No symptoms or CA-125 elevation
  • ❌ Radiation exposure (though one CT is minimal risk)
  • ❌ Cost
  • ❌ NCCN Guidelines don't mandate routine scans for asymptomatic early-stage patients
  • ❌ Clinical visits + CA-125 monitoring may be sufficient

My Assessment for Your Situation

If I had to recommend: A CT scan around your 2-year mark (July or September 2026) makes reasonable sense for you specifically because:

  1. You have clear cell cancer — higher recurrence risk warrants extra vigilance
  2. You have normal CA-125 — a clear CT validates that this marker is working for you
  3. You're transitioning from high-risk to lower-risk surveillance — a clear scan supports this transition
  4. You've completed aggressive treatment — a reassurance scan is reasonable at this milestone

However: This should be YOUR oncologist's decision based on:

  • Their experience with clear cell patients
  • Your individual risk factors
  • Your anxiety level and preference
  • Whether you've had any concerning symptoms

What to Do Now (Before July 2026)

Don't wait until July to decide. Bring this up at your next oncology visit:

  1. Ask directly: "Should I have a CT scan around my 2-year mark?"
  2. Explain your thinking: "I want to know if a clear scan would help guide my future surveillance"
  3. Discuss timing: "Would July or September matter?"
  4. Get the plan in writing: Know exactly what the surveillance strategy is going forward

Bottom Line

July 2026 is a reasonable time to discuss a CT scan with your oncologist. It's not too early (you're at the 2-year milestone), and it serves a purpose (reassurance + baseline for future comparison).

But the decision should be made collaboratively with your oncologist, not based on a calendar date alone. The key question is: "Will this CT change how we manage you going forward?" If yes, it's worth doing. If it's just routine, your clinical visits + CA-125 monitoring may be sufficient.


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines Version 3.2025 — Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer (Monitoring/Follow-up and Less Common Ovarian Cancers sections)

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: